GW&K Investment Management LLC Increases Stock Holdings in Vericel Co. (NASDAQ:VCEL)

GW&K Investment Management LLC raised its holdings in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 2.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,273,964 shares of the biotechnology company's stock after buying an additional 30,180 shares during the quarter. GW&K Investment Management LLC owned about 2.58% of Vericel worth $69,953,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Geneva Capital Management LLC raised its holdings in Vericel by 61.4% in the 3rd quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company's stock valued at $46,660,000 after buying an additional 420,078 shares during the period. Wellington Management Group LLP boosted its position in shares of Vericel by 214.0% during the 3rd quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company's stock worth $24,837,000 after purchasing an additional 400,667 shares during the period. Congress Asset Management Co. increased its holdings in Vericel by 37.4% in the 3rd quarter. Congress Asset Management Co. now owns 1,291,720 shares of the biotechnology company's stock valued at $54,575,000 after purchasing an additional 351,550 shares during the last quarter. TimesSquare Capital Management LLC raised its position in Vericel by 54.8% in the third quarter. TimesSquare Capital Management LLC now owns 590,145 shares of the biotechnology company's stock valued at $24,934,000 after purchasing an additional 209,009 shares during the period. Finally, Polar Asset Management Partners Inc. acquired a new position in Vericel during the third quarter worth $4,973,000.

Remove Ads

Insider Activity at Vericel

In other Vericel news, Director Paul K. Wotton sold 2,600 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $58.72, for a total value of $152,672.00. Following the completion of the sale, the director now owns 27,402 shares in the company, valued at approximately $1,609,045.44. The trade was a 8.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the transaction, the director now owns 26,595 shares in the company, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,100 shares of company stock valued at $618,872 in the last three months. 5.20% of the stock is currently owned by company insiders.

Vericel Trading Up 3.1 %

Shares of NASDAQ VCEL traded up $1.55 during mid-day trading on Tuesday, reaching $51.06. The company had a trading volume of 371,773 shares, compared to its average volume of 414,836. Vericel Co. has a 52-week low of $39.12 and a 52-week high of $63.00. The stock has a market cap of $2.52 billion, a P/E ratio of 851.08 and a beta of 1.72. The firm has a 50 day simple moving average of $57.05 and a two-hundred day simple moving average of $51.90.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on VCEL. BTIG Research boosted their price objective on Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. HC Wainwright reiterated a "buy" rating and set a $60.00 price target on shares of Vericel in a research note on Friday. StockNews.com lowered shares of Vericel from a "hold" rating to a "sell" rating in a research note on Friday. Truist Financial reaffirmed a "buy" rating and set a $61.00 target price (down from $67.00) on shares of Vericel in a research note on Monday. Finally, Stephens reissued an "overweight" rating and issued a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Vericel presently has an average rating of "Moderate Buy" and an average target price of $62.29.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.